Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LBL-047 in Healthy Adults and Systemic Lupus Erythematosus
NCT07323173Phase 1Recruiting
- Sponsor
- Leads Biolabs
- Start
- Dec 2025
- Primary completion
- Dec 2027
- Modality
- Monoclonal Antibodies, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in systemic lupus erythematosus (SLE) comparing LBL-047 for Injection with LBL-047 placebo for injection (2 arms). Primary endpoint: Occurrence of Treatment-Emergent adverse event (TEAE) and serious adverse event (SAE) at 89 days. Started Dec 2025; status: recruiting.
02
Drugs
LBL-047
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT07323173.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07323173.